Referring patients for esketamine (Spravato®) treatment: Who, Where, and How?

One of the important treatment options to consider for patients who suffer from major depressive disorder—NOT for all patients, but for some of them—is esketamine nasal spray (Spravato^®).

But most clinicians don’t themselves provide treatment with esketamine nasal spray and need to know exactly WHOM to refer for this treatment, WHERE to refer, and HOW to refer, that is, what exactly do referring clinicians need to do.

In this article, we’ll provide you with everything you need to know about these issues.

Here are links to our other articles about esketamine nasal spray (Spravato^®):

Esketamine nasal spray (brand name Spravato): Basic information

What does “treatment-resistant depression” in the indication for esketamine (Spravato®) mean?

How well does esketamine nasal spray (Spravato®) work for treatment-resistant depression?

Common and other side effects of esketamine nasal spray (Spravato®) 

Dissociation and perceptual disturbances with esketamine nasal spray (Spravato®)

Esketamine nasal spray (Spravato®): Clinical trials in “treatment-resistant depression”

Stimulants in a patient receiving ketamine/ esketamine?

What about concomitant medications during ketamine or esketamine treatment?